Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2019 | Possibilities for the use of pembrolizumab in lymphoma treatment

John Kuruvilla • 11 Nov 2019
iwNHL 2019
B-Cell Lymphoma CNS Lymphoma Diffuse Large B-Cell Lymphoma Hodgkin Lymphoma Lymphoma Non-Hodgkin Lymphoma Brentuximab vedotin Checkpoint inhibitors Nivolumab Pembrolizumab

John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, Canada, speaking at the 17th International Workshop on Non-Hodgkin Lymphoma, Boston, MA, discusses the use of pembrolizumab in the treatment of varying lymphomas. Dr Kuruvilla discusses the parallels between Hodgkin lymphoma and primary mediastinal lymphoma, and suggests an increase in usage of the drug as treatment for Richter transformation, CNS disease, and testicular involvement.

More from John Kuruvilla

Evolving treatment landscape of MCL
John Kuruvilla et al. • 17 Oct 2023
1:06
Updates on the Phase Ib KEYNOTE-013 trial: pembrolizumab in NHL
John Kuruvilla • 12 Dec 2022
1:18
Hodgkin lymphoma highlights at ASH 2022 and future outlooks
John Kuruvilla • 12 Dec 2022
0:49
Abbv-319: a novel, CD19-GRM antibody-drug conjugate being explored for R/R B-cell malignancies
John Kuruvilla • 12 Dec 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals